

**Table S1.** Perceived stress scale (PSS) and awakening cortisol (AUC and Cmax, mmol/L) at baseline, week 4, 8 and 12 in the ITT population (mean (SEM), LPHEAL9 (n=63-65), Placebo (n=62-64))

|  | Baseline     | 4 weeks         | 8 weeks         | 12 weeks        |
|--|--------------|-----------------|-----------------|-----------------|
| <i>PSS Total score<sup>1</sup></i>         |              |                 |                 |                 |
| LPHEAL9                                    | 18.05 (0.37) | 16.03 (0.66)*** | 13.78 (0.52)*** | 12.91 (0.58)*** |
| Placebo                                    | 17.98 (0.42) | 14.75 (0.70)*** | 14.45 (0.64)*** | 13.19 (0.68)*** |
| <i>Awakening cortisol AUC<sup>2</sup></i>  |              |                 |                 |                 |
| LPHEAL9                                    | 835.3 (48.9) | 711.9 (38.6)**  | 756.8 (47.6)*   | 687.2 (43.8)**  |
| Placebo                                    | 936.5 (48.8) | 869.8 (62.4)    | 773.0 (49.8)*** | 806.8 (55.4)*   |
| <i>Awakening cortisol Cmax<sup>2</sup></i> |              |                 |                 |                 |
| LPHEAL9                                    | 17.78 (1.12) | 15.05 (0.82)*   | 16.35 (0.99)    | 14.97 (0.90)*   |
| Placebo                                    | 19.96 (1.04) | 18.67 (1.54)*   | 17.04 (1.06)**  | 17.71 (1.18)*   |

<sup>1</sup> No significant differences between groups at any timepoint in change from baseline. Within group differences compared to baseline were significantly different for all timepoints for both groups \*\*\*p<0.001 (Paired t-test).

<sup>2</sup> No significant differences between groups at any timepoint in change from baseline. Within group differences compared to baseline \* p<0.05, \*\* p<0.01, \*\*\*p<0.001 (Related samples Wilcoxon signed rank test).

**Table S2.** Profile of mood scores (POMS) at baseline, week 12 and change over time in the ITT population (mean (SEM), LPHEAL9 (n=65), Placebo (n=64))

|                               | Baseline     | 12 weeks     | Change<br>baseline-w12 | P, comparison<br>between groups <sup>1</sup> |
|-------------------------------|--------------|--------------|------------------------|--|
| <i>Total mood disturbance</i> |              |              |                        |  |
| LPHEAL9                       | 20.50 (2.02) | 9.10 (2.05)  | -11.40 (2.26)***       | 0.161  |
| Placebo                       | 18.38 (2.11) | 10.59 (2.43) | -7.79 (2.23)***        |  |
| <i>Anger-Hostility</i>        |              |              |                        |  |
| LPHEAL9                       | 5.52 (0.43)  | 3.38 (0.42)  | -2.13 (0.51)***        | 0.211 <sup>2</sup>                           |
| Placebo                       | 5.31 (0.56)  | 3.75 (0.48)  | -1.56 (0.44)***        |  |
| <i>Confusion-Bewilderment</i> |              |              |                        |  |
| LPHEAL9                       | 5.73 (0.47)  | 4.10 (0.43)  | -1.63 (0.44)***        | 0.051  |
| Placebo                       | 5.23 (0.44)  | 4.77 (0.47)  | -0.47 (0.51)           |  |
| <i>Depression-Dejection</i>   |              |              |                        |  |
| LPHEAL9                       | 3.23 (0.40)  | 2.33 (0.35)  | -0.90 (0.42)*          | 0.221 <sup>3</sup>                           |
| Placebo                       | 2.89 (0.41)  | 2.40 (0.42)  | -0.49 (0.44)           |  |
| <i>Fatigue-Inertia</i>        |              |              |                        |  |
| LPHEAL9                       | 9.40 (0.57)  | 7.37 (0.55)  | -2.04 (0.61)*          | 0.759  |
| Placebo                       | 9.43 (0.59)  | 7.19 (0.64)  | -2.25 (0.63)***        |  |
| <i>Tension-Anxiety</i>        |              |              |                        |  |
| LPHEAL9                       | 8.04 (0.56)  | 4.96 (0.44)  | -3.08 (0.56)***        | 0.269  |
| Placebo                       | 7.73 (0.52)  | 5.76 (0.53)  | -1.97 (0.55)***        |  |
| <i>Vigour-Activity</i>        |              |              |                        |  |
| LPHEAL9                       | 11.42 (0.48) | 13.04 (0.64) | 1.62 (0.60)*           | 0.472  |
| Placebo                       | 12.23 (0.51) | 13.28 (0.60) | 1.05 (0.51)*           |  |
| <i>Friendliness</i>           |              |              |                        |  |
| LPHEAL9                       | 15.57 (0.47) | 17.12 (0.50) | 1.54 (0.48)**          | 0.345  |
| Placebo                       | 15.79 (0.53) | 16.68 (0.54) | 0.90 (0.52)            |  |

<sup>1</sup> Between group differences: Independent-Samples Mann-Whitney U Test<sup>2</sup> p=0.086 (Between groups Mixed two-way between-within group ANOVA including all timepoints)<sup>3</sup> p=0.088 (Between groups Mixed two-way between-within group ANOVA including all timepoints)

\* p&lt;0.05, \*\* p&lt;0.01, \*\*\*p&lt;0.001 (t-test, within group difference)

**Table S3.** Quality of sleep (PSQI) at baseline, week 12 and change over time in the ITT population (mean (SEM), LPHEAL9 (n=65), Placebo (n=64))

|                              | Baseline    | 12 weeks    | Change<br>baseline-w12 | P, comparison<br>between groups |
|------------------------------|-------------|-------------|------------------------|---------------------------------|
| <i>Total score</i>           |             |             |                        |                                 |
| LPHEAL9                      | 6.05 (0.33) | 4.94 (0.32) | -1.11 (0.33)***        | 0.958                           |
| Placebo                      | 6.58 (0.36) | 5.36 (0.33) | -1.22 (0.29)**         |                                 |
| <i>Duration of sleep</i>     |             |             |                        |                                 |
| LPHEAL9                      | 0.85 (0.10) | 0.82 (0.10) | -0.03 (0.11)           | 0.307                           |
| Placebo                      | 1.08 (0.10) | 0.89 (0.10) | -0.19 (0.09)           |                                 |
| <i>Sleep disturbance</i>     |             |             |                        |                                 |
| LPHEAL9                      | 1.25 (0.05) | 1.06 (0.06) | -0.18 (0.07)*          | 0.288                           |
| Placebo                      | 1.20 (0.06) | 1.09 (0.05) | -0.11 (0.05)**         |                                 |
| <i>Sleep latency</i>         |             |             |                        |                                 |
| LPHEAL9                      | 1.35 (0.11) | 1.05 (0.09) | -0.31 (0.10)**         | 0.343                           |
| Placebo                      | 1.59 (0.12) | 1.14 (0.12) | -0.45 (0.12)***        |                                 |
| <i>Daytime dysfunction</i>   |             |             |                        |                                 |
| LPHEAL9                      | 1.00 (0.07) | 0.72 (0.07) | -0.28 (0.09)***        | 0.727                           |
| Placebo                      | 0.88 (0.06) | 0.67 (0.07) | -0.20 (0.07)           |                                 |
| <i>Sleep efficiency</i>      |             |             |                        |                                 |
| LPHEAL9                      | 0.54 (0.09) | 0.43 (0.09) | -0.11 (0.10)           | 0.994                           |
| Placebo                      | 0.70 (0.12) | 0.59 (0.11) | -0.11 (0.10)           |                                 |
| <i>Overall sleep quality</i> |             |             |                        |                                 |
| LPHEAL9                      | 1.05 (0.06) | 0.86 (0.09) | -0.18 (0.09)*          | 0.591                           |
| Placebo                      | 1.08 (0.06) | 0.95 (0.08) | -0.12 (0.09)           |                                 |

Between group differences: Independent-Samples Mann-Whitney U Test

\* p&lt;0.05, \*\* p&lt;0.01, \*\*\*p&lt;0.001 (Within group, Friedman's test, all timepoints included)

**Table S4.** Cognition tests at baseline, week 12 and change over time in the ITT population (mean (SEM)).

|   | Baseline      | 12 weeks      | Change<br>baseline-w12 | P, comparison<br>between groups |
|---|---------------|---------------|------------------------|---------------------------------|
| <b>Word recall, % accuracy</b>                  |               |               |                        |                                 |
| LPHEAL9 (n=65)                                  | 42.8 (1.9)    | 49.3 (2.2)    | 6.6 (1.9)**            | <0.001                          |
| Placebo (n=64)                                  | 46.3 (1.8)    | 43.6 (2.0)    | -2.7 (1.9)             |                                 |
| <b>Numeric working memory test</b>              |               |               |                        |                                 |
| <i>Accuracy (%)</i>                             |               |               |                        |                                 |
| LPHEAL9 (n=65)                                  | 92.3 (1.0)    | 91.0 (2.2)    | -1.2 (2.4)             | 0.374 <sup>1</sup>              |
| Placebo (n=64)                                  | 89.1 (2.4)    | 92.2 (1.2)    | 3 (2.3)                |                                 |
| <i>Reaction time (msec)</i>                     |               |               |                        |                                 |
| LPHEAL9 (n=65)                                  | 1271.9 (36.6) | 1145.4 (29.1) | -126.2 (24.9)***       | 0.081 <sup>1</sup>              |
| Placebo (n=64)                                  | 1241.3 (41.0) | 1152.1 (40.4) | -79.7 (24.1)**         |                                 |
| <b>Rapid visual information processing test</b> |               |               |                        |                                 |
| <i>Accuracy (%)</i>                             |               |               |                        |                                 |
| LPHEAL9 (n=65)                                  | 33.81 (2.10)  | 41.38 (2.41)  | 7.58 (1.98)***         | 0.361                           |
| Placebo (n=64)                                  | 33.16 (2.72)  | 43.40 (2.77)  | 10.23 (2.12)***        |                                 |
| <i>Reaction time (msec)</i>                     |               |               |                        |                                 |
| LPHEAL9 (n=65)                                  | 535.7 (9.7)   | 508.8 (10.3)  | -26.9 (14.7)           | 0.051 <sup>2</sup>              |
| Placebo (n=64)                                  | 520.1 (9.2)   | 504.6 (15.7)  | -15.5 (16.7)           |                                 |
| <b>Paired associate learning</b>                |               |               |                        |                                 |
| <i>Total Errors</i>                             |               |               |                        |                                 |
| LPHEAL9 (n=63)                                  | 17.6 (2.6)    | 12.9 (2.1)    | -4.7 (2.0)*            | 0.113                           |
| Placebo (n=60)                                  | 15.0 (2.6)    | 14.7 (2.5)    | -0.4 (1.7)             |                                 |
| <i>Mean errors to success</i>                   |               |               |                        |                                 |
| LPHEAL9 (n=63)                                  | 3.6 (0.6)     | 2.7 (0.5)     | -0.9 (0.5)*            | 0.048 <sup>2</sup>              |
| Placebo (n=60)                                  | 2.8 (0.7)     | 3.3 (0.6)     | 0.4 (0.6)              |                                 |

Between group differences: Mixed two-way between-within group ANOVA

<sup>1</sup> Mann-Whitney U Test<sup>2</sup> Outliers removed

\* p&lt;0.05, \*\* p&lt;0.01, \*\*\*p&lt;0.001 (Within group, Wilcoxon signed rank test).

**Table S5.** Inflammation markers in serum at baseline, week 12 and change over time in the ITT population (mean (SEM)).

|                                       | <b>Baseline</b> | <b>12 weeks</b> | <b>Change<br/>baseline-w12</b> | <b>P, comparison<br/>between groups</b> |
|---------------------------------------|-----------------|-----------------|--------------------------------|---|
| <i>BDNF (ng/ml)</i>                   |                 |                 |                                |   |
| LPHEAL9 (n=65)                        | 33.64 (1.18)    | 32.87 (1.03)    | -0.77 (0.85)                   | 0.857                                   |
| Placebo (n=63)                        | 33.59 (0.85)    | 32.63 (0.95)    | -0.96 (0.60)                   |   |
| <i>TGF-<math>\beta</math> (ng/ml)</i> |                 |                 |                                |   |
| LPHEAL9 (n=64)                        | 59.33 (1.86)    | 59.24 (1.84)    | -0.09 (1.75)                   | 0.176                                   |
| Placebo (n=63)                        | 58.76 (1.63)    | 55.63 (1.58)    | -3.13 (1.38)*                  |   |
| <i>Fractalkine (pg/ml)</i>            |                 |                 |                                |   |
| LPHEAL9 (n=65)                        | 1150 (23.77)    | 1149 (24.17)    | -0.78 (17.18)                  | 0.133                                   |
| Placebo (n=61)                        | 1193 (30.33)    | 1247 (40.21)    | 54.33 (29.05)                  |   |
| <i>Galectin-3 (ng/ml)</i>             |                 |                 |                                |   |
| LPHEAL9 (n=65)                        | 8.85 (0.24)     | 8.71 (0.24)     | -0.14 (0.18)                   | 0.690                                   |
| Placebo (n=63)                        | 8.84 (0.26)     | 8.81 (0.28)     | -0.03 (0.21)                   |   |

Between group differences: Independent-Samples t-test

\* p&lt;0.05 (Within group, paired t-test)